Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
JOHNSON & JOHNSON	JNJ	Nyse +17 Other	7,358,013	154.6 USD	Stock
JOHNSON & JOHNSON	000943981	Berne S.E.	-	140 CHF
JOHNSON & JOHNSON	JNJ	Deutsche Boerse AG	972	141.9 EUR
JOHNSON & JOHNSON	JNJ *	Mexican S.E.	1,197	2,568 MXN
JOHNSON & JOHNSON	JNJ	Swiss Exchange	-	136 USD
JOHNSON & JOHNSON	JNJ	Frankfurt	3,341	141.5 EUR
JOHNSON & JOHNSON	JNJ	Wiener Boerse	-	140.8 EUR
JOHNSON & JOHNSON	0R34	London S.E.	1,164	149.3 USD
JOHNSON & JOHNSON	JNJ	Börse Stuttgart	566	142.2 EUR
JOHNSON & JOHNSON	JNJ	Bolsa De Valores De Colombia	23	589,000 COP
JOHNSON & JOHNSON	JNJ	Lima	-	144.5 USD
JOHNSON & JOHNSON	JNJ	Santiago S.E.	-	148.3 USD
JOHNSON & JOHNSON	JNJ	BOERSE MUENCHEN	2,617	142.2 EUR
JOHNSON & JOHNSON	4JNJ	Borsa Italiana	-	139.6 EUR
JOHNSON & JOHNSON	JNJ	Bulgaria S.E.	6	138.7 EUR
JOHNSON & JOHNSON	JNJCL	Santiago S.E.	-	155,930 CLP
JOHNSON & JOHNSON	JNJ_KZ	Kazakhstan S.E.	13	152.1 USD
JOHNSON & JOHNSON	JNJ	Swiss Exchange	-	500 CHF
JOHNSON & JOHNSON	JNJ	Buenos Aires S.E. +1 Other	10,565	11,386 ARS	Stock
JOHNSON & JOHNSON	JNJD	Buenos Aires S.E.	569	10.9 USD
JOHNSON & JOHNSON	JNJB34	Sao Paulo	6,541	52.45 BRL	Stock
JOHNSON & JOHNSON	JNJ0	Deutsche Boerse AG +1 Other	-	13.5 EUR	Stock
JOHNSON & JOHNSON	JNJ	NEO Exchange	9,822	20.71 CAD
JOHNSON CONTROLS INTERNATIONAL PLC	JCI	Nyse +7 Other	6,167,298	69.02 USD	Stock
JOHNSON CONTROLS INTERNATIONAL PLC	TYIA	Deutsche Boerse AG	105	62.55 EUR
JOHNSON CONTROLS INTERNATIONAL PLC	JCI1 N	Mexican S.E.	0	1,120 MXN
JOHNSON CONTROLS INTERNATIONAL PLC	0Y7S	London S.E.	26	67.13 USD
JOHNSON CONTROLS INTERNATIONAL PLC	TYIA	Börse Stuttgart	-	63.43 EUR
JOHNSON CONTROLS INTERNATIONAL PLC	TYIA	BOERSE MUENCHEN	112	63.32 EUR
JOHNSON CONTROLS INTERNATIONAL PLC	TYIA	Frankfurt	22	53.62 EUR
JOHNSON CONTROLS INTERNATIONAL PLC	TYIA	Berne S.E.	-	- CHF
JOHNSON OUTDOORS INC.	JOUT	Nasdaq	71,131	36.94 USD	Stock
PRISM JOHNSON LIMITED	PRSMJOHNSN	Bombay S.E. +1 Other	29,958	143.8 INR	Stock
PRISM JOHNSON LIMITED	PRSMJOHNSN	NSE India S.E.	464,319	143.6 INR
JOHNSON MATTHEY PLC	JMPLY	OTC Markets	1,071	46.93 USD	Stock
JOHNSON PHARMACARE LIMITED	SUNSHINE6	Bombay S.E.	1,645,392	1.1 INR	Stock
JOHNSON MATTHEY PLC	JMAT	London S.E. +6 Other	280,234	1,845 GBX	Stock
JOHNSON MATTHEY PLC	JMT2	Deutsche Boerse AG	-	21.1 EUR
JOHNSON MATTHEY PLC	JMAT N	Mexican S.E.	-	811 MXN
JOHNSON MATTHEY PLC	JMT2	Börse Stuttgart	-	21.24 EUR
JOHNSON MATTHEY PLC	JMT2	BOERSE MUENCHEN	-	21.72 EUR
JOHNSON MATTHEY PLC	JMPLF	OTC Markets	908	23.3 USD
JOHNSON MATTHEY PLC	JMAT	Berne S.E.	-	- CHF

See all

News (681)

Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	05-06	AQ
US employment boom leaves factory workers behind	04-04	RE
Republicans hope to win Black voters for Trump. It won't be easy	04-02	RE
Zions Bancorporation N A : 2023 Annual Report Officers & Directors	03-28	PU
RELX : Notice of 2024 Annual General Meeting	03-08	PU
CORUS ENTERTAINMENT APPLAUDS ITS CREATIVE TEAMS AND PRODUCTION PARTNERS ON 65 CANADIAN SCREEN AWARDS NOMINATIONS	03-06	AQ
Johnson & Johnson - RYBREVANT in Combination with Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	03-04	AQ
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	03-01	PR
JELD-WEN Appoints Antonella Franzen to Board of Directors	02-21	PR
JELD-WEN Holding, Inc. Announces Board Changes	02-21	CI
The Trump voters in swing states who are returning to the fold	01-13	RE
The toll on migrants of a free bus north from the border	01-11	RE
Arcadium Lithium plc completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.	01-03	CI
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer	12-22	AQ
Voter advocates, conservative activists brace for 2024 election showdowns	12-07	RE
Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer	12-05	AQ
Asset manager GMO's first ETF will focus on 'quality' companies	11-13	RE
Johnson & Johnson : Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib	23-10-23	PU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	23-10-23	PU
Janssen Pharmaceutical - Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate plus Prednisone	23-10-23	AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations	23-10-23	AQ
Janssen Pharmaceutical - Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer	23-10-23	AQ
Janssen Pharmaceutical - TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guerin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer	23-10-23	AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-MuscleInvasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations	23-10-23	AQ
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-23	PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor	23-10-23	PU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23-10-20	PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor	23-10-20	PU
Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO	23-10-16	PU
Transcript : Accuray Incorporated - Analyst/Investor Day	23-10-03
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	23-09-27	PU
Janssen Pharmaceutical - Treatment with RYBREVANT and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer	23-09-12	AQ
Salesforce Gives $20M to Education, Expanding Pathways into Tech and AI Careers	23-09-11	BU
Janssen - Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT plus Chemotherapy	23-09-07	AQ
Johnson & Johnson : Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations	23-08-30	PU
Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non Small Cell Lung Cancer	23-08-24	PU
The Cigna Group Foundation and YMCA Partner To Improve Community Vitality in Five Cities	23-08-16	PR
Transcript : Nanobiotix S.A. - Special Call	23-07-10
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference	23-06-08	GL
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference	23-06-08	AQ
Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT and Lazertinib Combination Therapy	23-06-05	AQ
McCarthy's moment: Debt ceiling vote secures Republican US House speaker's standing	23-06-01	RE
SEALED AIR CORP/DE : Submission of Matters to a Vote of Security Holders (form 8-K)	23-05-22	AQ
Livent Corporation signed a definitive agreement to acquire Allkem Limited in a merger of equals transaction for $6.4 billion.	23-05-09	CI
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer	23-05-01	AQ

1234NextSee all

Companies (46)

JOHNSON & JOHNSON 371 B $

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, ...

JOHNSON & JOHNSON 371 B $

ROYALTY PHARMA PLC 12 573 M $

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-ca ...

ALLEGION PLC 10 964 M $

Allegion plc specializes in manufacturing and marketing security systems. Products are sold under the Cisa, Interflex, LCN, Schlage, Von Duprin, Aptiq, Bocom, Briton, Bricard, Dexter, Falcon, Glynn-Johnson, Ito Kilit, Ives, Kryptonite, Legge, Normbau, Ste ...

KENVUE INC. 43 201 M $

Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: ...

JOHNSON CONTROLS INTERNATIONAL PLC 45 992 M $

Johnson Controls International Plc specializes in the design, manufacturing and marketing of equipment for the regulation and safety of buildings. Net sales break down by family of products and services as follows: - building regulation, integrated manag ...

PRISM JOHNSON LIMITED 902 M $

Prism Johnson Limited is an India-based building materials company. The Company operates through four segments: Cement, Tile and Bath (HRJ), and Ready Mixed Concrete (RMC). The Cement segment has a cement production capacity of 5.6-meganewton tons at Satn ...

JOHNSON SERVICE GROUP PLC 861 M $

Johnson Service Group PLC provides textile rental and related services across the United Kingdom and the Republic of Ireland. The Company's Workwear business is a supplier of workwear and protective wear in the United Kingdom, offering these services thro ...

1234Next

Insiders

Suzanne Johnson

Suzanne Nora Johnson is currently the Chairman at Intuit, Inc., Co-Chairman-Trustees Board at The Brookings Institution, Chairman at The John & Mary R.
Markle Foundation, Inc., Independent Director at Pfizer Inc., Treasurer & Director at TechnoServe, Inc., Director at Pfizer, Inc., Director at Americas Frontier Fund, Trustee at the University of Southern California, Member of the American Academy of Arts & Sciences, Member of The World Economic Forum USA, Inc., Member of the American Red Cross, Inc., and Member of the Global Agenda Council.
Previously, she served as Vice Chairman at The Goldman Sachs Group, Inc., Chairman at Global Markets Institute, Independent Director at American International Group, Inc., Director-Governing Board at The American National Red Cross, and Independent Director at Visa, Inc. She also held positions as Director at The Goldman Sachs Foundation and Co-Chair-Trustees Board at Carnegie Institution of Washington.
Ms. Johnson completed her undergraduate studies at the University of Southern California and obtained a graduate degree from Harvard Law School.

Suzanne Johnson

Suzanne K. Johnson

Suzanne Lehmann Johnson

Suzanne Jiggens Johnson

Suzanne Johnson

Suzanne Johnson-Walsh

No results for this search